旭輝: 去年交付11.8萬套新房 刷新歷史年度交付紀錄
旭輝(00884.HK)官方公眾號發布年度總結,去年全國61城、137個項目,共交付11.8萬套新房,其中,9,675戶提前交付,超過4,300戶實現「交房即交證」。交付量較2022年的9萬套增長超過30%,並刷新旭輝成立以來的年度交付紀錄。
旭輝控股董事會主席林中在新年獻詞中表示,行業深度調整進入第三個年頭,對旭輝人來說2024不會輕鬆,在可能面臨更多困難之下,將竭盡全力衝刺8萬套新房的交付目標。
林中指,長期而言,房地產市場的調整一定有益於中國經濟增長和可持續發展,房地產行業將會完成向高品質發展模式的轉型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.